RecruitingPhase 2NCT07659795

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma (TARGET-D 203)

Sponsor

Verastem, Inc.

Enrollment

150 participants

Start Date

Jul 1, 2026

Study Type

INTERVENTIONAL

Conditions

Colorectal, Cancer

Summary

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Cetuximab + mFOLFOX6, a drug called VS-7375, and others for people with colorectal, cancer. The study is currently recruiting participants at 5 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVS-7375

Taken by mouth

DRUGcetuximab

Intravenous infusion

DRUGpanitumumab

Intravenous infusion

DRUGCetuximab + mFOLFOX6

Intravenous infusion

Locations(7)

START Los Angeles

Los Angeles, California, United States

START Midwest

Grand Rapids, Michigan, United States

START New Jersey

East Brunswick, New Jersey, United States

START Dallas Fort Worth

Fort Worth, Texas, United States

START Mountain Region

West Valley City, Utah, United States

Icon Cancer Centre South Brisbane

South Brisbane, Queensland, Australia

Icon Cancer Centre Adelaide

Kurralta Park, South Australia, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07659795

Related Trials

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

NCT0706665720 locations

A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

NCT0752520627 locations

IDOV-Immune for Advanced Solid Tumors

NCT069106575 locations

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

NCT0697411015 locations

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

NCT0731880513 locations